# US 2026/0272302 A1 · Systems and methods of analyzing and interfacing with combined imaging and spectroscopy data for the brain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0272302 A1
- Document ID: US20260272302A1
- Status: Published application
- Kind: A1
- Application number: 19/539,840
- Filed: 2026-02-13
- Published: 2026-09-17
- Earliest claimed: 2019-11-27
- Assignees: BrainSpec Inc.
- Applicants: BrainSpec Inc.
- Inventors: Alex Zimmerman; Alexander Lin
- Web page: https://patentgrep.com/patent/US20260272302A1

## CPC

- A61B 5/0042: {for the brain}
- A61B 5/14507: {specially adapted for measuring characteristics of body fluids other than blood (devices for taking samples of body liquids A61B10/0045)}
- A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes}
- A61B 5/4088: {Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia}
- A61B 5/4866: {Evaluating metabolism (using breath test A61B5/083)}
- A61B 5/743: {Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G01R 33/5608: {Data processing and visualization specially adapted for MR, e.g. for feature analysis and pattern recognition on the basis of measured MR data, segmentation of measured MR data, edge contour detection on the basis of measured MR data, for enhancing measured MR data in terms of signal-to-noise ratio by means of noise filtering or apodization, for enhancing measured MR data in terms of resolution by means for deblurring, windowing, zero filling, or generation of gray-scaled images, colour-coded images or images displaying vectors instead of pixels (image data processing or generation, in general G06T)}
- G06T 11/26: Drawing of charts or graphs
- G16H 30/20: for handling medical images, e.g. DICOM, HL7 or PACS
- G16H 30/40: for processing medical images, e.g. editing
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- A61B 2576/026: for the brain
- G01R 33/46: NMR spectroscopy
- G01R 33/485: based on chemical shift information {[CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

In part, the disclosure relates to an analysis system in communication with one or more sources of brain region or brain tissue-specific spectroscopy data; and computer-executable logic, encoded in memory of the analysis system, for interpreting brain region or brain tissue-specific spectroscopy data, where the computer-executable logic is configured for execution of: processing the brain region or brain tissue-specific spectroscopy data to obtain one or more spectroscopic graphical representations of the brain region or brain tissue-specific spectroscopy data; co-registering such representations with regions of interest in imaging data obtained relative thereto, where the imaging data is obtained simultaneously with the spectroscopy data; and displaying a first visual representation of co-registered brain region or brain tissue-specific spectroscopy data and imaging data. The visual representation may include one or more views of brain tissue and a spatially correlated map of changes in brain region or tissue-specific spectroscopy data.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A diagnostic spectroscopic system, comprising:
an analysis system in communication with one or more sources of brain region spectroscopy data; and
computer-executable logic, encoded in a memory device of the analysis system, for interpreting brain region spectroscopy data, wherein the computer-executable logic is configured for execution of:
selecting a brain region for analysis, wherein the brain region is identified relative to imaging data;
filtering the brain region spectroscopy data based on one or more data-quality metrics, wherein brain region spectroscopy data failing at least one data-quality metric threshold is excluded from classification; and
generating one or more metabolite specific thresholds using a set of ranges of two or more parameters selected from the group consisting of (i) a metabolite profile, (ii) a patient age, (iii) an echo time, and (iv) a field strength of magnetic resonance imaging (MRI);
classifying the filtered brain region spectroscopy data according to the one or more metabolite specific thresholds into high, low, or within a normal range; and
displaying brain tissue-specific spectroscopy data.

### Claim 22 (depends on 21)

The system of claim 21, wherein the brain region spectroscopy data is magnetic resonance spectroscopy (MRS) data.

### Claim 23 (depends on 22)

The system of claim 22, wherein the brain tissue-specific spectroscopy data comprises metabolite data and further comprising classifying the metabolite data using the one or more metabolite specific thresholds.

### Claim 24 (depends on 23)

The system of claim 23, wherein the metabolite data is generated in response to one or more drugs.

### Claim 25 (depends on 24)

The system of claim 24, wherein the metabolite data is evaluated over a course of treatment to analyze responsiveness of a disease or pathology in response to a treatment comprising the one or more drugs.

### Claim 26 (depends on 25)

The system of claim 25, wherein the computer-executable logic is further configured for execution of: selecting one or more voxels in the brain tissue-specific spectroscopy data to determine specific metabolite concentrations.

### Claim 27 (depends on 21)

The system of claim 21, wherein the computer-executable logic is configured for execution of classifying the brain region spectroscopy data using a machine learning system trained on a dataset of diseased and normal spectra for brain metabolites.

### Claim 28 (depends on 21)

The system of claim 21, wherein the brain region spectroscopy data is acquired using chemical shift imaging (CSI) comprising phase-encoding to spatially encode a volume divided into a plurality of voxels.

### Claim 29 (depends on 24)

The system of claim 24, wherein the computer-executable logic is further configured for execution of generating a disease-specific metabolic profile based on the classified brain region spectroscopy data, wherein the disease-specific metabolic profile corresponds to one or more of brain tumors, stroke, seizure disorders, Alzheimer's disease, depression, or multiple sclerosis.

### Claim 30

A diagnostic spectroscopic analysis system, comprising:
an analysis module, a data storage, and one or more hardware resources, in communication with one or more sources of brain region or brain tissue-specific spectroscopy data; and
computer-executable logic, encoded in a memory device of the analysis system, for interpreting brain region or brain tissue-specific spectroscopy data, wherein the computer-executable logic is configured for execution of:
decoding magnetic resonance imaging (MRI) vendor-specific proprietary spectroscopy data formats for multiple MRI devices into a common format such that data from different MRI devices may be used by the analysis system;
processing the brain region or brain tissue-specific spectroscopy data to obtain one or more spectroscopic graphical representations of the brain region or brain tissue-specific spectroscopy data from multiple MRI device vendors;
classifying the brain region or brain tissue-specific spectroscopy data into a classification of increased, decreased, or within a selected range by generating a metabolite specific threshold based two or more parameters selected from the group consisting of metabolite profile, patient age, echo time, and field strength of MRI;
determining indicia corresponding to reference ranges for a metabolite, wherein one or more of the reference ranges are determined using one or more range parameters, wherein the reference ranges are generated using statistical analysis of healthy control data to create bounds for upper, lower, and normative ranges for a selected metabolite ratio; and
displaying brain tissue-specific spectroscopy data.

### Claim 31 (depends on 30)

The system of claim 30, wherein the computer-executable logic is further configured for execution of monitoring changes in brain biochemistry through a course of treatment using the brain tissue-specific spectroscopy data, and correlating the monitored changes with treatment outcomes.

### Claim 32 (depends on 30)

The system of claim 30, wherein the analysis system is in communication with cloud resources comprising one or more libraries of MR spectra used to classify the brain region or brain tissue-specific spectroscopy data.

### Claim 33 (depends on 30)

The system of claim 30, wherein decoding the MRI vendor-specific proprietary spectroscopy data formats comprises parsing and decoding unique file formats from each of a plurality of MRI vendors to enable analysis of spectroscopy data irrespective of the MRI device used for data acquisition.

### Claim 34 (depends on 30)

The system of claim 30, wherein classifying the brain region or brain tissue-specific spectroscopy data comprises determining whether a metabolite concentration is (A) below a given threshold indicating abnormality, (B) above or below a given threshold indicating abnormality, or (C) above a given threshold indicating abnormality.

### Claim 35 (depends on 30)

The system of claim 30, wherein the computer-executable logic is further configured for execution of co-registering the one or more spectroscopic graphical representations with regions of interest in imaging data obtained relative to brain tissue, wherein the imaging data is obtained simultaneously with the brain region or brain tissue-specific spectroscopy data.

### Claim 36 (depends on 30)

The system of claim 30 wherein the computer-executable logic is further configured for execution of: selecting one or more voxels in the brain tissue-specific spectroscopy data to determine specific metabolite concentrations.

### Claim 37

A method of analyzing metabolite levels in brain tissue comprising:
processing brain region or brain tissue-specific spectroscopy data to obtain one or more spectroscopic graphical representations of the brain region or brain tissue-specific spectroscopy data;
analyzing brain tissue-specific spectroscopy data to identify metabolite data or data derived from metabolite data measured relative to brain tissue of a subject using magnetic resonance spectroscopy (MRS);
generating one or more metabolite specific thresholds using a set of ranges of two or more parameters selected from the group consisting of a metabolite profile, patient age, echo time, and field strength of magnetic resonance imaging (MRI); and
displaying a first visual representation of a brain tissue-specific spectroscopy data, wherein the first visual representation comprises a set of indicia corresponding to a classification based on the one or more metabolite specific thresholds.

### Claim 38 (depends on 37)

The method of claim 37 further comprising: displaying a reference range relative to the first visual representation, wherein the reference range comprises a scaling of results on a zero to one-hundred percentile rating based on the two or more parameters selected.

### Claim 39 (depends on 37)

The method of claim 37, wherein the first visual representation includes indicia corresponding to upper, lower and reference ranges for a metabolite, wherein one or more of the ranges are determined using the set of ranges of a plurality of parameters, wherein the set of range parameters comprises profile, patient age, pulse sequence, echo time, and field strength of MRI.

### Claim 40 (depends on 37)

The method of claim 37, further comprising monitoring changes in brain biochemistry through a course of treatment, using the brain tissue-specific spectroscopy data, the course of treatment comprising one or more drugs; and correlating the changes with treatment outcomes to determine responsiveness to the one or more drugs.

### Claim 41 (depends on 37)

The method of claim 37, further comprising generating a disease-specific metabolic profile based on the classification, wherein the disease-specific metabolic profile corresponds to one or more of: brain tumors, stroke, seizure disorders, Alzheimer's disease, depression, or multiple sclerosis.
